Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

PaperCitations, authors & open-access status

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 545 citations, 2012 year and green oa status.

545
Citations
2012
Year
green
OA Status

Related on ScholarIQ

Leslie A. Fecher
Author
The Lancet Oncology
Journal
Melanoma and MAPK Pathways
Topic
Melanoma and MAPK Pathways
Topic
Cutaneous Melanoma Detection and Management
Topic
Ocular Oncology and Treatments
Topic
470M+ articles · free account